Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
Provided By GlobeNewswire
Last update: Mar 26, 2025
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant)
Read more at globenewswire.com1.41
-0.06 (-4.08%)
Find more stocks in the Stock Screener
VANI Latest News and Analysis
